Compare ABVE & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABVE | ONCY |
|---|---|---|
| Founded | 2019 | 1998 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Pharmaceuticals and Biotechnology |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.5M | 94.0M |
| IPO Year | N/A | 1999 |
| Metric | ABVE | ONCY |
|---|---|---|
| Price | $2.11 | $1.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 1.4M | 721.5K |
| Earning Date | 01-01-0001 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $213,446,206.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.25 | $0.33 |
| 52 Week High | $6.56 | $1.51 |
| Indicator | ABVE | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 49.65 | 64.34 |
| Support Level | $1.96 | $0.98 |
| Resistance Level | $2.28 | $1.08 |
| Average True Range (ATR) | 0.22 | 0.08 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 54.08 | 88.21 |
Above Food Ingredients Inc is a differentiated, regenerative ingredient company. Its products are made with real nutritious, flavorful ingredients and delivered with transparency. Its vision is to create a healthier world one seed, one field, and one bite at a time. With a robust chain of custody of plant proteins, enabled by scaled operations and infrastructure in primary agriculture and processing, and proprietary seed development capabilities that leverage the power of artificial intelligence driven genomics. The company delivers nutritious foods to businesses and consumers with traceability and sustainability. Above Food's consumer products and brands are available in grocers across Canada and the United States.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.